How could the FDA's approval of a new biologic regimen affect the Center for Biologics Evaluation and Research?
CBER's regulatory scope expands with approval of Skyrizi for Crohn's disease The approval of the subcutaneous induction regimen of risankizumab (Skyrizi) for Crohn's disease represents a significant regulatory milestone for the Center for Biologics Evaluation and Research (CBER). CBER is the specialized division within the FDA responsible for evaluating and approving biologic products. The approval is based on data from the AFFIRM trial, which showed the subcutaneous regimen achieved clinical remission in 55% of patients at week 12 compared to 29.6% for placebo.
- Effect
- Mild positive
- How direct
- Brind's reasoning
- When
- Right away
- The story
- Gone quiet
How it reaches Center for Biologics Evaluation and Research
-
The FDA approved a subcutaneous induction regimen of risankizumab (Skyrizi) for adults with moderate to severe Crohn’s disease. This approval expands the previous authorization, which was for an intravenous induction followed by subcutaneous maintenance. The new regimen allows patients to begin induction therapy at home using an on-body injector induction pack.
The full event1independent outlet -
As the specialized center within the FDA, the Center for Biologics Evaluation and Research is responsible for the evaluation and approval of biologic products like risankizumab. The approval of this new regimen falls directly under CBER's regulatory purview, expanding the scope of its oversight.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
FDA research center
Everything about Center for Biologics Evaluation and Research
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- The FDA approved a subcutaneous induction regimen of risankizumab for adults with moderate to severe Crohn’s disease.healio.com
- The AFFIRM trial showed risankizumab achieved clinical remission at week 12 in 55% of patients vs. 29.6% for placebo.healio.com
- Risankizumab was previously approved in 2022 as an IV induction regimen followed by subcutaneous maintenance.healio.com
Why it matters
CBER's mandate is to ensure the safety and efficacy of advanced biologic therapies. The approval of a new, more flexible regimen like Skyrizi increases the complexity and volume of the regulatory oversight CBER must manage. This demonstrates the center's role in facilitating patient access to modern, effective treatments for inflammatory bowel disease.
This approval builds on the strong efficacy of Skyrizi, which was initially approved in 2022. The expansion to subcutaneous induction reflects a broader trend in pharmaceutical development toward giving patients and physicians greater flexibility in how advanced therapies are initiated.
What we don't know yet
- What specific post-market surveillance requirements will CBER impose on the new subcutaneous induction regimen?
- How will the increased volume of biologic approvals affect CBER's resource allocation?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- healio.comOct 23
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.